End-payors' settlement with Merck, Glenmark in Zetia US antitrust case gets final approval
MLex Summary: End-payor plaintiffs secured final approval for their $70 million settlement with Merck and Glenmark to resolve US claims accusing the drug companies of conspiring to keep a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article